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Summary
We have found that two chemokines, recombinant gro-a and gro-(3, specifically inhibit growth
factor-stimulated proliferation of capillary endothelial cells in a dose-dependent manner, whereas
gro-y has no inhibitory effect. In vivo, gro-P inhibits blood vessel formation in the chicken
chorioallantoic membrane assay. It is sufficiently potent to effectively suppress basic fibroblast
growth factor-induced corneal neovascularization after systemic administration in mice. Fur-
ther, gro-P significantly inhibits the growth of murine Lewis lung carcinoma in syngeneic
C57B16/J and immunodeficient nude mice without toxicity. In vitro, Lewis lung carcinoma
cells are completely insensitive to recombinant gro-P at high concentrations that significantly
inhibit endothelial cell proliferation. This finding supports the conclusion that gro-(3 inhibits
Lewis lung tumor growth by suppression oftumor-induced neovascularization.
Angiogenesis, the formation of new capillaries from
preexisting blood vessels, is a fundamental process in-
volved in embryonic development and in pathological con-
ditions such as tumorigenesis, diabetic retinopathy, and wound
healing (1). The process ofangiogenesis in vivo is regulated
both by angiogenic stimulators such as fibroblast growth fac-
tors (FGFs)l and vascular endothelial growth factor (VEGF)
(2, 3), and by angiogenic inhibitors such as thrombospon-
din and angiostatin (4, 5) . Tumor growth is an angiogenesis-
dependent process that requires the stimulation ofnew ves-
sel growth (6) . Tumors may locally generate an imbalance
of angiogenic stimulation over inhibition by increasing the
expression ofangiogenic inducers or by decreasing the pro-
duction ofangiogenic suppressors. The identification ofen-
dogenous angiogenesis inhibitors may be useful for treat-
ment of cancer and diabetic retinopathy.
Chemokines are members of a large superfamily of struc-
turally and functionally related inflammatory cytokines that
stimulate the chemotactic migration ofdistinct sets ofcells,
including neutrophils, monocytes, lymphocytes, and fibro-
blasts. gro-(x, gro-R, gro-'Y are members of a superfamily of
small (8-10-kD), inducible, and secreted proinflammatory
cytokines that all share four conserved cysteines (7). Two
subfamilies can be distinguished according to the positions of
the first two cysteines, which are either separated by one
'Abbreviations used in this paper: BCE, bovine capillary endothelial; bFGF,
basic fibroblast growth factor; CAM, chick chorioallantoic membrane;
FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor.
amino acid (-C-X-C- family) or are adjacent to each other
(-C-C- family) . Although each subfamily of chemokines has
a common chemoattractant function for leukocytes and has
a unique chromosomal location ofgenes (chromosome 4 for
-C-X-C- proteins and chromosome 17 for -C-C- proteins),
little is known about other distinct functions of the members
of each family. The recent characterization of two -C-X-C-
chemokines as angiogenic regulators (PF-4 as an angiogenic
inhibitor and IL-8 as an angiogenic stimulator) (8-10) may
help us to understand the physiological functions ofthe gro
chemokines in the control of angiogenesis in vivo. In the
present study, we investigated the antiangiogenic activities
of gro chemokines by analyzing their effects on endothelial
cells in vitro and in vivo, and on tumor growth in vivo.
Materials and Methods
Reagents, Cells, and Animals.
￿
Recombinant human gro-a, gro-R,
gro-'Y, and IL-8 expressed from Escherichia coli were purified by
HPLC-coupled chromatography (R&D Systems Inc., Minneapo-
lis, MN) . Recombinant PF-4 was a generous gift of Dr. Theo-
dore E. Maione (Repligen Corp., Cambridge, MA). Bovine capil-
lary endothelial (BCE) cells were obtained as previously described
(11) and were maintained in DME with 10% heat-inactivated bo-
vine calfserum, antibiotics, and 3 ng/ml recombinant human ba-
sic FGF (bFGF) (Scios Nova Inc., Mountainview, CA). The Lewis
lung tumor cell line was maintained in culture in DME supple-
mented with 10% FCS (Hyclone Laboratories, Logan, UT) and
antibiotics. Male 6-8-wk-old C57B16/J mice (The Jackson Labo-
ratory, Bar Harbor, ME) and nude mice (Massachusetts General
Hospital, Boston, MA) were used for tumor studies. Animals were
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IL) chamber before all procedures and were observed until fully
recovered. Animal studies were reviewed andapproved by the ani-
mal care and use committee ofChildren's Hospital (Boston, MA)
and are in accordance with the guidelines of the Department of
Health and Human Services (U.S. Department of Agriculture) .
Iodination Labeling.
￿
For iodination labeling, 5 NLg of recombi-
nant human gro-P and 5 la,g IODO-GEN (Pierce, Rockford, IL)
were dissolved in chloroform in afinalvolume of 100 pl. The gro-P
and IODO-GEN mixture was dried in a glass tube by evaporating
the reagent with dried nitrogen gas. The reagents were dissolved
in 0.2 M phosphate buffer, pH 7.2. Na
1211 (New England Nu-
clear, Boston, MA) (500 ~LCi) wasaddedto the reaction andincu-
bated 15 min at room temperature. The reaction was terminated
by addition of 50 p,l of 10 mM KCI, 10% TCA, and 1 mg/ml
BSA. Labeled protein was separated from unincorporated reagents
on Sephadex G-25 (Pharmacia Biotech, Inc., Piscataway, NJ). Spe-
cific activity of the 1211-gro-[3 was 15 cpm pg-' .
Heparin-binding Chromatography.
￿
Approximately 10 N,g ofpu-
rified gro-ot, gro-R, gro-y, and PF-4 was loaded onto a heparin
TSK7m-gel column (7.5 mm X 7.5 cm) in a phosphate buffer (20
mM sodium phosphate, pH 7.5). The proteins were eluted with a
linear gradient of NaCl in 20 mM sodium phosphate buffer, pH
7.5), at a rate of 1 ml/min. Fractions of 1 ml were collected and
measured for protein concentrations at 280 nm.
DNA SynthesisAssayfor Capillary Endothelial Cells.
￿
BCE cells
were seeded in 48-well plates (10,000 cells per well) and grown
in DME supplemented with 10% bovine calf serum. After 24 h,
the medium was replaced with fresh DME (GIBCO BRL, Gaith-
ersburg, MD) containing 2% bovine calf serum, 1 mM thymi-
dine, and 0.5% BSA. The cells were incubated in 10% C02 at
37°C for 48 h, and samples (recombinant gro-a, gro-R, gro-.y,
and PF-4) at different concentrations were added to the cells in
the presence of 1 ng/mlbFGF. After 16 h ofincubation, 0.5 p,Ci
of [3H]thymidine in 10 [L1 PBS was added to each well. 5 h later,
the medium was aspirated and the cells were washed twice with
PBS. The cells were incubated on ice with two 5-min methanol
and two 10-min 5% TCA incubations. The fixed cells were
washed once with distilled water and solubilized in 200 p,l of 0.3-M
NaOH. The incorporated radioactivity was determined in a scin-
tillation counter (Wallac, Gaithersburg, MD).
Proliferation Assayfor Capillary Endothelial Cells and Tumor Cells.
A 72-h BCE cell proliferation assay was performed as previously
described (7). For the tumor cell proliferation assay, Lewis lung
carcinoma cells (8,000 cells perwell) were plated onto 24-well tis-
sue culture plates and were incubated in DME medium (0.5 ml/
well) containing 5% FCS and antibiotics for 24 h, and each sam-
ple in triplicate was added to cells. After 72 h, adherent andnon-
adherent cells were dispersed in trypsin, resuspended in Hematall
(Fisher Scientific Co., Pittsburgh, PA), and counted by Coulter
counter.
Chick Chorioallantoic Membrane (CAM) Assay.
￿
3-d-old fertilized
white Leghorn eggs (Spafas, Inc., Norwich, CT) were cracked,
and chick embryos with intact yolks were placed in 100 X 20
mm plastic petri dishes. After 3 d of incubation in 3% C02 at
37°C, a disk of methylcellulose containing a chemokine protein
was implanted on the CAM of individual embryos. The disks
were made by desiccation of 10 Wl of 45% methylcellulose (in
HZO) . After 48 h of incubation, embryos and CAMS were ana-
lyzed for the formation ofavascular zones by astereomicroscope.
Mouse Corneal Micropocket Assay.
￿
6-wk-old male C57B16/J mice,
each -20 g, were dividedinto three groups. Control animals (n =
9) received daily intraperitoneal injections of 0.2-0.3 ml PBS.
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Onegroup ofanimals (n = 5) received daily intraperitoneal injec-
tions of 15 mg/kg gro-P in 0.2 ml PBS, including pretreatment
with the same dose of gro-P for 2 d before corneal implantation.
The third group of animals (n = 3) received daily intraperitoneal
injections of 100 mg/kg gro-P in 0.3 ml PBS beginning on the
day of corneal implantation. A corneal micropocket was created
in both eyes of each mouse as previously described (7). Into this
pocket, pellets containing sucrose aluminum sulfate (Bukh Med-
itec, Copenhagen, Denmark), hydron polymertype NCC (Inter-
feron Sciences, Inc., NewBrunswick, NJ), and 80-100 ng ofbFGF
were implanted as previously described (7). The corneas ofallmice
were photographed by means ofa slit-lamp stereomicroscope at a
magnification of 10 on the sixth day after corneal implantation.
Maximal vessel length and clock hours of circumferential neovas-
cularization were measured.
Histology.
￿
Animals were killed on day 6 after corneal implanta-
tion, andeyes were enucleated andfixedin 10% phosphate-buffered
formalin. Eyes were embedded in paraffin accordingto standard his-
tological procedures. Cross-sections ofthe eye (5 R,m thick) were
permeabilized with 0.2 M HClfor 10 min. The sections were pro-
cessed andstainedwith arabbit antiserumagainst human von Wille-
brand factor (Dako Corp., Carpinteria, CA) as previously described.
TumorStudies in Mice.
￿
Male 6-8-wk-old C57B16/J and immu-
nodeficient nude mice were used for tumor studies. Lewis lung
carcinoma cells (1 X 10') growing in log phase were harvested,
resuspended in PBS, andimplanted subcutaneously in the midline
dorsum of each animal in a volume of 100 [,l . Four mice were
used in each treatment or control group. Intralesional injections
with either 100 Rl PBS or 100 N,g of gro-P in 100 p.l PBS were
begun shortly after injection of tumor cells and continued once
daily for a total of 14-15 treatments. Visible tumors were present
within 24 h. Primary tumors were measured blindly using digital
calipers on the days indicated.
Results and Discussion
Amino Acid Sequence Alignmentand Heparin-binding Affinity
of Human Chemokines . The overall sequence identity and
consensus amino acids were obtained by comparing gro-ot,
gro-(3, gro-y, PF-4, and IL-8 afterremoval of NHZ-terminal
signal sequences (Fig. 1 a) . The gro proteins share high se-
quence identity with each other (86-90%) . In the 000H-
terminal region, they are homologous with PF-4 (54%
identity), including a shared cluster of positively charged
lysines (Fig. 1 b), whereas they are less homologous to IL-8
(15% identity) in this region (Fig. 1 a) . Recombinant hu-
man -C-X-C- chemokines (PF-4, IL-8, gro-o, gro-(3, and
gro-y) expressed from E. coli, were purified to >95% ho-
mogeneity as revealed by SDS gel analysis (Fig. 1 c) . The
gro-P protein in vitro at a concentration of0.5 mg/ml is in
equilibrium between monomeric and dimeric forms (Fig. 1
d), suggesting that these chemokines with a similar back-
bone structure may be active in either form (12), The gro
proteins are heparin-binding molecules with a similar affin-
ity as evidenced by elution from a heparin-Sepharose col-
umn with 0.5 M NaCl. PF-4, which eluted from an identi-
cal column with 1.0 M NaCl, has a higher affinity for
heparin (Fig. 1 e) .
Inhibition of DNA Synthesis ofEndothelial Cells by gro Chemo-
kines. To determine whether the gro family could inhibit
the proliferation of endothelial cells in vitro, recombinant
Regulation ofAngiogenesis and Tumor Growth by gro Chemokineshuman gro proteins were incubated with BCE cells (11)
stimulated bybFGF . At the concentration of 10 lt,M, gro-(x
and gro-P each inhibited DNA synthesis by 56%, which was
less potent than recombinant PF-4 (76% inhibition) (Fig. 2
a) . The dose-dependent inhibition ofDNA synthesis ofBCE
cells by gro-P correlates with the inhibition of cell prolif-
eration (Fig . 2 c) . No distinct morphology associated with
apoptotic endothelial cells such as rounding, detachment,
and fragmentation of cells could be detected, even after a
3-d incubation with gro-P (Cao, Y ., unpublished data) .
Recombinant gro-y, however, which shares 87 and 86%
amino acid sequence identities with gro-ot and gro-(3, re-
spectively (Fig . 1 a), had no inhibitory activity on bovine
capillary endothelial cells (Fig . 2, a and b) . Previous studies
reported that the inhibition of angiogenesis by PF-4 could
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Inhibition ofDNA synthesis and prolifera-
tion ofcapillary endothelial cells by chemokines (a and
b) BCE cells were seeded in 48-well plates (10,000 cells
per well) and grown in DME supplemented with 10%
BCS as described in Materials and Methods. Recombi-
nant chemokines at different concentrations were
added to cells containing 1 ng/ml bFGF in the pres-
ence and absence of heparin (10 U/ml) . 24 h later,
[3H]thymidine was added to each well. Radioactivity
was measured 5 h later, (a) in the absence of heparin,
(b) in the presence of 10 U/ml heparin. O, PF-4; !],
' 0 ' J
￿
, .J
￿
bFGF alone ; A, gro-a ; " , gro-I3 ; " , gro-y. (c) Re-
10 100 1000 10000
￿
combmant human gro[3 at different concentrations -
be reproduced by a synthetic peptide derived from the
COOH-terminal 13 amino acids of PF-4, which contains a
cluster of positively charged lysines (8) . Although all three
gro proteins share high degrees ofsequence homology with
PF-4 in the COOH-terminal region, gro-y has one amino
acid substitution (from lysine to glutamine) at position 64
in the conserved lysine-enriched region (Fig. 1, a and b) .
The same lysine to glutamine substitution at position 64 is
also found in IL-8 (Fig . 1 a) . In contrast to PF-4, IL-8 has
been reported to be a potent angiogenic factor (10, 13) .
Thus, the substitution of a lysine residue by glutamine in
the COOH terminus may contribute to the lack of endo-
thelial cell inhibitory activity of gro-y and IL-8 .
Unlike PF-4, the inhibitory activities o£gro-1x and -R on
BCE cells could not be abrogated by addition of soluble
Gro-beta OM)
Figure 1 . Amino acid sequence alignment
and biochemical characterization of human
chemokines. (a and b) The sequences for five
-C-X-C- chemokines (gro-a, gro-[3, gro-y,
PF-4, and IL-8) are aligned according to their
conserved cysteines. Identical and conserved
amino acids are boxed and shaded. (c) SDS-
PAGE analysis ofpurified recombinant chemo-
kines under reducing conditions. 5 N.g of each
protein was loaded onto a 15% SDS gel fol-
lowed by staining with Coomassie blue . (d)
Chemical cross-linking of 1251-recombinant
human gro-[3 . The labeling was performed as
described in Materials and Methods . Lane 1,
1251-gro-[3 without disuccinimidyl suberate
cross-linker. Lane 2, 1251-gro-[3 (0 .5 mg/ml) in-
cubated with disuccinimidyl suberate at room
temperature for 30 min . 5 ng of each sample
was analyzed by SDS-PAGE . (e) Elution profile
ofpurified gro-a, gro-[3, gro-y, and PF-4 from
a heparin TSK-gel column .
was tested on BCE cells in the presence of 1 ng/ml
bFGF in a 72-h proliferation assay as described in Ma
terials and Methods . gro-P inhibited capillary endothelial cell proliferation in a dose-dependent manner (O) . Recombinant gro-[3 at doses up to 10 IiM
did not inhibit proliferation of murine Lewis lung carcinoma cells (") in vitro . Values represent the mean of three determinations (± SEM) as percent-
ages ofinhibition or stimulation .
No Heparin Heparin
----------
r~r
-----------heparin (10 U/ml; Sigma Chemical Co., St. Louis, MO) to
the culture medium (Fig. 2 b) . In contrast, the antiprolifer-
ative activity of PF-4 was largely abolished by heparin (Fig.
2 b) . Previous reports have suggested that PF-4 may block
the low-affinity binding sites of bFGF composed ofheparan
sulfate proteoglycans and thereby inhibit angiogenesis in-
duced by bFGF (14, 15). Although gro chemokines are hep-
arin-binding proteins, their affinity for heparin (0.5 M
NaCl elution) appears to be too low to interfere with bind-
ing of bFGF to heparan sulfate proteoglycans on the cell
surface and in the extracellular matrix. Further, the 000H-
terminal 13 amino acids of and a mutant analogue derived
from PF-4, both do not bind to heparin yet inhibit angiogen-
esis (9). These findings argue against blockage of heparan
sulfate proteoglycan-binding sites for bFGF as a mechanism
for the angiostatic effects of these chemokines. Whether the
inhibition of angiogenesis by these chemokines is mediated
by a specific receptor(s) expressed on endothelial cells or by
other alternative mechanisms must be determined. Our pre-
liminary results obtained by cross-linking 1211-gro-R, and
1211-PF-4 to bovine capillary endothelial cells indicate that
no specific high-affinity receptors for these chemokines are
present on endothelial cells (Cao . Y., unpublished data).
Inhibition ofAngiogenesis in the Chick Embryo by gro-(3.
￿
To
study the angiostatic activity in vivo, recombinant gro pro-
teins were tested on the CAM (16, 17). At a concentration
of 10 Vg/disk, gro-P inhibited new vessel growth in all chick
embryos tested as measured by the formation of avascular
zones (Fig. 3, a and c). Vessel regression around the avascu-
lar zone was seen in the chick membranes implanted with
gro-P disks (Fig. 3, a, inset). The measured inhibition ofgro-P
was dose dependent, and no detectable inflammation was ob-
served. gro-(x and gro-y had moderate inhibitory effects on
new vessel growth in this assay. These results confirm our
in vitro data that gro-P is a specific inhibitor for endothelial
cells.
Inhibition ofMouse Corneal Neovascularization by gro-P.
￿
To
further investigate the antiangiogenic activity ofgro-P in vivo,
the effect ofsystemic administration ofgro-P on bFGF-stimu-
lated neovascularization in the mouse cornea was studied.
This bioassay requires that a putative angiogenesis inhibitor
be administered systemically (e.g., intraperitoneal injection)
to test its ability to suppress bFGF-induced neovasculariza-
tion in the cornea. This is a rigorous assay that can discrimi-
nate between the many substances inhibiting angiogenesis in
the chick embryo, or in in vitro assays, and those few com-
pounds that are sufficiently potent to inhibit angiogenesis in
remote sites such as the cornea when induced by a relatively
high dose of 80 ng bFGF. Systemic treatment with gro-P
inhibited bFGF-stimulated corneal neovascularization in a
dose-dependent manner (Fig. 4) . The length of growing
vessels was inhibited in a dose-dependent manner by intra-
peritoneal injections of gro-P from 15 mg/kg (P <0.002)
up to 100 mg/kg (P <0 .001), (inhibition of length of
-40%). There was no significant difference in clock hours
of circumferential neovascularization in treated animals
compared with control animals (Fig. 4 f). The density of
new vessels in the gro-(3-treated animals was also markedly
reduced as compared with that of control animals (Fig. 4, a
and b) . The treated mice did not experience weight loss over
the course of treatment, indicating that no toxicity was
caused by the pharmacological dose ofgro-R.
Since gro-P acts as a chemoattractant for neutrophils, the
observed inhibition of vessel growth may be due to an in-
direct effect mediated by these inflammatory cells. However,
histological examination of corneas implanted with bFGF
pellets from gro-R-treated animals and control animals re-
vealed no significant differences in the number ofinflamma-
tory cells within the corneal stroma (Fig. 4, c and d). In the
control animals, vessels stained by an antibody against von
Willebrand factor (18) can be seen within the corneal stroma
adjacent to the implanted FGF pellet (Fig. 4 c) . No vessels
are seen in the corneal section from gro-R-treated animals
(Fig. 4 d) . These findings support the data obtained from the
in vitro endothelial cell proliferation assay and the CAM
assay that gro-P has direct inhibitory effects on new vessel
growth.
Reversible Inhibition of Primary Tumor Growth by gro-(3 In
Vivo. To determine if gro-P could inhibit primary tumor
growth, recombinant gro-P protein was used to treat
C57B16/J mice bearing subcutaneous Lewis lung carcino-
mas. Daily intralesional injections of 100 N,g of gro-P per
20 g mouse completely suppressed the growth of primary
tumors during the 14-d treatment course (Fig. 5 a) . In con-
trast, tumors grew rapidly to sizes >200 mm' in all saline-
treated animals during the same 14-d treatment period. Upon
termination of the intralesional injections of gro-R, regrowth
of tumors was observed in 75% of the gro-R-treated ani-
mals within 6 wk after tumor implantation (Fig. 5 b). Tu-
mors in animals treated with saline continued to grow expo-
nentially to >7,000 mm, leading to the demise ofall animals
on day 40 after tumor implantation. To exclude the possi-
bility that an immune response induced by gro-P was in-
volved in its antitumor activity, immunodeficient nude mice
were also used to determine the antitumor effect of gro-P.
As shown in Fig. 5 c, the growth of Lewis lung carcinoma
in nude mice was also significantly inhibited by intrale-
sional injection of gro-P although the efficacy ofinhibition
(-60%) was not as potent as that observed in immunocom-
petent mice (Fig. 5, a and b). These data support the notion
that suppression of Lewis lung tumor growth by gro-P is
mediated by inhibition of tumor-induced angiogenesis. It
would be interesting to investigate if gro-P can also sup-
press the growth of other tumors.
Inhibition of Cell Proliferation by gro-/3 Is Speci isfor Endothe-
lial Cells but Notfor Tumor Cells. To further exclude the
possibility that the antitumor activity of gro-P was due to
direct effects on tumor cells, gro-P was tested in vitro on
Lewis lung carcinoma cells and endothelial cells in a 72-h
proliferation assay. At a concentration of 10 p.M gro-R, the
proliferation of BCE cells was significantly inhibited by
-40% (Fig. 2 c) . The inhibition of endothelial cell prolifer-
ation occurred in a dose-dependent manner, whereas pro-
liferation of Lewis lung carcinoma cells was not affected at
all doses used. These results are consistent with the inhibi-
tory effects of gro-P on DNA synthesis of endothelial cells
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Figure 3 .
￿
Antiangiogenic effects ofgro-a,
gro-R, gro-- y, and PF-4 on the CAM .
Methylcellulose disks containing 10 ~Lg of
each protein were implanted on CAMS of
6-d-old chick embryos as described. After
48 h, the formation of avascular zones was
analyzed. (a) An example of gro-R-
implanted CAM . The area of the avascular
zone is marked by curved arrows . White ar-
rowheads point to the implanted disk (2-mm
diameter) . High magnification insert of the
area marked by an asterisk reveals the re-
gressed vessels (arrows) in the adjacent area of
the avascular zone. (b) A control CAM with
methylcellulose disk (arrowheads) containing
saline . (c) At a concentration of 10 pLg/disk,
the number ofCAMS with avascular zones
over the total number of CAMS tested for
each protein is indicated above each bar.2074
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Inhibition of the growth of Lewis
lung carcinoma in syngeneic C57B16/J and im-
munodeficient nude mice by recombinant human
gro-(3. (a) Recombinant gro-(3 (") and PBS (O)
were tested for their effects on subcutaneous tu-
mor growth in C57B16/J mice. gro-(3 protein at a
final concentration of 1.0 mg/ml was injected in-
tralesionally in volume of 100 lLI per mouse
shortly after the implantation oftumor cells once
daily through day 13. Primary tumors were mea-
sured blindly using digital calipers on the days in-
dicated. For days 0-13, data represent the mean
tumor volumes (±SEM) of surviving mice in
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each group. (b) Treatments were discontinued af-
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￿
ter day 13, and primary tumor volumes were
measured as above. 40 d after tumor implanta-
tion, all animals in the control group died. For days 13-40, data for the saline-treated animals represent the mean tumor volumes ({ SEM) ofsurviving
mice (O), whereas data for the gro-(3-treated animals are represented individually for each animal from days 13-47 (O, 0, A, and A) . (c) Recombinant
gro-(3 (") and PBS (O) were examined for their effects on subcutaneous tumor growth in nude mice. The intralesional treatments were carried out using
the same procedures as described (a), except treatments were continued through day 14. For days 0-15, data represent the mean tumor volumes (± SEM)
ofsurviving mice in each group.
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(Fig. 2, a and b), suggesting that gro-(3 is an angiogenesis in-
hibitor with no direct effect on proliferation of Lewis lung
tumor cells.
The -C-X-C- chemokines have previously been identi-
fied to be chemotactic for certain populations ofleukocytes,
such as neutrophils that are involved in the inflammatory re-
sponse. The physiological functions of these proteins in vivo,
however, remain to be characterized, since their in vitro ac-
tivities do not always predict their predominant in vivo ef-
fects. To date, two members of the -C-X-C- family, IL-8
and PF-4, have been shown to be involved in the regula-
tion of angiogenesis (8-10). IL-8 has been shown to be a
potent stimulator of angiogenesis, and PF-4 has been found
to be an inhibitor of angiogenesis. These opposing activi-
ties related to the regulation of angiogenesis by a family of
structurally related proteins suggest the presence of multi-
ple, yet divergent, biological functions of the chemokines.
Recently, proliferin and proliferin-related protein, two mem-
bers of the prolactin and growth hormone family, have been
shown to have opposing regulatory effects on angiogenesis
during placenta formation (19). It is interesting to speculate
on the role of certain -C-X-C- chemokines during the in-
flammatory response. The up-regulation of an angiogenic
chemokine such as IL-8 and the down-regulation ofangio-
static chemokines such as PF-4 and gro-(3 may accelerate
angiogenesis during wound healing. In the later phases of
inflammation, the expression ofangiogenic chemokines may
be switched off while the expression of angiostatic chemo-
Figure 4.
￿
Inhibition of mouse corneal neovascularization by systemic administration of gro-(3. Pellets containing sucrose aluminum sulfate, hydron,
and 80-100 ng of bFGF were implanted into corneal micropockets of mice as described in Materials and Methods. Corneas were photographed by slit-
lamp stereomicroscopy on day 6 after bFGF pellet implantation. (a) Cornea of control mouse receiving daily intraperitoneal injections of saline. (b) Cornea
ofmouse treated with daily intraperitoneal injections of 100 mg/kg gro-(3. Immunohistochemical staining ofcross-sections ofmouse corneas using anti-
bodies to von Willebrand factor. P, the location ofthe implanted pellet. (c) Saline-treated animal. (d) Animal treated with intraperitoneal injection of 100
mg/kg gro-(3 administered as intraperitoneal injection. Arrows point to stained vessels within corneal stroma. CE, corneal epithelium; CP, corneal pocket;
IC, inflammatory cells; P, pellet. Bar, 20 ym. Quantitation ofcorneal neovascularization was performed on day 6 after bFGF pellet implantation. (e) Max-
imal vessel length. (f) Clock hours ofcircumferential neovascularization .
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kines are switched on. In this respect, it would be impor-
tant to examine the expression levels ofthese chemokines dur-
ing all phases of inflammation. Recently, Hoogewerf et al.
(20) have discovered that the -C-X-C- chemokines, CTAP-
III and NAP-2, are heparan sulfate-degrading enzymes.
The degradation of heparan sulfate in the extracellular ma-
trix and on the cell surface may play a key role in the regu-
lation of angiogenesis, since angiogenic factors such as bFGF
and VEGF exert their functions by interacting with both spe-
cific high affinity receptors and heparan sulfate proteogly-
cans on the cell surface.
Comparison of amino acid sequence homology reveals
that, in the COOH-terminal region, gro chemokines share
high sequence homologies with the 13 amino acids ofPF-4
(Fig. 1, a and b), which has been reported to be an angio-
static peptide (8) . Mutations of crucial amino acids in this
region, such as a positively charged lysine in position 64
(conserved among PF-4, gro-a, and gro-(3) to glutamine in
gro-y and IL-8 (Fig. 1 a), may lead to the loss of angiostatic
activity. Since the genes for -C-X-C- chemokines are lo-
cated in the same region (q21) of chromosome 4 because of
gene duplication (7), the mutations caused by gene dupli-
cation during evolution may explain the divergence of bio-
logical activities of these chemokines.
An increasing number of endogenous angiogenic inhibi-
tors, including the recently isolated angiostatin from our lab-
oratory (5), have been identified in the last decade. It should
be emphasized that gro-(3 is one ofthe few angiogenesis in-
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(n=3) (n=3) ~ (n=3)
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(/ 4) ~~ ,.dhibitors that can effectively inhibit bFGF-induced neovas-
cularization in the mouse cornea after systemic administra-
tion. The expression oftwo other endogenous endothelial cell
inhibitors, thrombospondin and glioma-derived angiogen-
esis inhibitory factor, has been reported to be controlled by
the tumor suppressor gene p53 (21, 22). The loss of func-
tion of the p53 gene leads to the down-regulation of these
two angiogenic inhibitors and may thereby promote tumor
growth. Whether other endogenous angiogenesis inhibitors
are controlled by tumor suppressor genes such as p53 re-
mains to be seen.
In the present study, we also show that gro-(3 is a potent
inhibitor of Lewis lung tumor growth in both immuno-
competent and immunodeficient mice without direct inhib-
itory activity on tumor cells. Like angiostatin and TNP-1470,
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